CO4930289A1 - Composiciones galenicas, en donde el ingrediente activo es un agente activo dificilmente soluble - Google Patents

Composiciones galenicas, en donde el ingrediente activo es un agente activo dificilmente soluble

Info

Publication number
CO4930289A1
CO4930289A1 CO99013726A CO99013726A CO4930289A1 CO 4930289 A1 CO4930289 A1 CO 4930289A1 CO 99013726 A CO99013726 A CO 99013726A CO 99013726 A CO99013726 A CO 99013726A CO 4930289 A1 CO4930289 A1 CO 4930289A1
Authority
CO
Colombia
Prior art keywords
fatty acid
carbon atoms
glyceryl
atoms
carbon
Prior art date
Application number
CO99013726A
Other languages
English (en)
Inventor
Michael Ambuhl
Barbara Luckel
Richter Friedrich
Barbara Haberlin
Armin Meinzer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269231&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO4930289(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9804742.6A external-priority patent/GB9804742D0/en
Priority claimed from GBGB9805104.8A external-priority patent/GB9805104D0/en
Priority claimed from GBGB9805199.8A external-priority patent/GB9805199D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO4930289A1 publication Critical patent/CO4930289A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se relaciona con un preconcentrado enemulsión o en microemulsión para administración oral, la cual comprende: 1. una ciclosporina o un macrólido, y un medio portador, el cual comprende: 2. un segundo componente seleccionado a partir del grupo que consiste en: i) citrato de trietilo o citrato de acetiltrietilo, ii) éster de ácido graso de 6 a 10 átomos de carbono de glicerilo de glicol de polietileno, iii) diéster de ácido graso de 6 a 16 átomos de carbono de glicerilo, iv) monoéster de ácido graso de 6 a 14 átomos de carbono de glicerilo, v) una mezcla de mono- y di-glicéridos de ácidos grasos de 6 a 16 átomos de carbono, vi) monoéster de ácido graso de 6 a 12 átomos de carbono de glicol de propileno, vii) ácido grasos y alcoholes, viii) pirrolidona N-metílica, ix) triacetato de glicerol, x) alcohol bencílico, y xi) éster o éster de alquilenpoliol, 3. un componente lipofílico, y 4. un tensoactivo, con la condición de que, cuando el componente 2): _ (a) consista en citrato de trietilo, la composición este exenta o sustancialmente exenta de etanol, y/o (b) consista en una mezcla de mono- y di-glicéridos de ácidos grasos de 8 a 10 átomos de carbono, la composición esté exenta o sustancialmente exenta de un triglicérido de ácido graso de 6 a 12 átomos d carbono.
CO99013726A 1998-03-06 1999-03-05 Composiciones galenicas, en donde el ingrediente activo es un agente activo dificilmente soluble CO4930289A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9804742.6A GB9804742D0 (en) 1998-03-06 1998-03-06 Organic compounds
GBGB9805104.8A GB9805104D0 (en) 1998-03-10 1998-03-10 Organic compounds
GBGB9805199.8A GB9805199D0 (en) 1998-03-11 1998-03-11 Organic compounds

Publications (1)

Publication Number Publication Date
CO4930289A1 true CO4930289A1 (es) 2000-06-27

Family

ID=27269231

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99013726A CO4930289A1 (es) 1998-03-06 1999-03-05 Composiciones galenicas, en donde el ingrediente activo es un agente activo dificilmente soluble

Country Status (30)

Country Link
EP (2) EP1354582A3 (es)
JP (2) JP2002505271A (es)
KR (1) KR100443306B1 (es)
CN (1) CN1195495C (es)
AR (1) AR015729A1 (es)
AT (1) ATE277599T1 (es)
AU (1) AU749217B2 (es)
BE (3) BE1012400A5 (es)
BR (1) BR9908597A (es)
CA (1) CA2322845C (es)
CO (1) CO4930289A1 (es)
CZ (1) CZ301967B6 (es)
DE (2) DE19983012T1 (es)
ES (1) ES2228014T3 (es)
FR (4) FR2775596B1 (es)
GB (1) GB2350791B (es)
HK (2) HK1034038A1 (es)
HU (1) HUP0101080A3 (es)
ID (1) ID25908A (es)
IL (2) IL138248A0 (es)
IT (1) IT1313550B1 (es)
MY (1) MY129274A (es)
NO (1) NO331800B1 (es)
NZ (1) NZ506644A (es)
PE (1) PE20000324A1 (es)
PT (1) PT1059913E (es)
SK (1) SK285139B6 (es)
TR (1) TR200002586T2 (es)
TW (3) TWI257870B (es)
WO (1) WO1999044584A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143580A0 (en) * 1998-12-11 2002-04-21 Pharmasolutions Inc Pharmaceutical compositions containing lipophilic drugs and methods for the preparation thereof
US7026290B1 (en) * 1998-12-30 2006-04-11 Dexcel Ltd. Dispersible concentrate for the delivery of cyclosprin
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
AU1043201A (en) * 1999-11-02 2001-05-14 Cipla Limited Cyclosporin formulation
WO2001032143A1 (en) * 1999-11-02 2001-05-10 Cipla Ltd. A pharmaceutical composition for the administration of water-insoluble pharmaceutically active substances and a process for preparation thereof
GB2362573A (en) * 2000-05-25 2001-11-28 Cipla Ltd Cyclosporin formulation
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
WO2003002095A1 (fr) * 2001-06-28 2003-01-09 Chugai Seiyaku Kabushiki Kaisha Preparation d'une micro-emulsion de type huile-eau
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
KR20040047056A (ko) * 2002-11-29 2004-06-05 한미약품 주식회사 비페닐디메틸디카복실레이트의 경구용 마이크로에멀젼조성물
US8802116B2 (en) 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
KR20040084240A (ko) * 2003-03-27 2004-10-06 (주) 코스메디 고형지질나노입자, 이를 함유하는 활성성분 전달용약학조성물 및 이의 제조방법
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
JP2008518931A (ja) * 2004-10-29 2008-06-05 ノバルティス アクチエンゲゼルシャフト 自発的に分散可能な医薬組成物
ES2573539T3 (es) 2005-03-21 2016-06-08 Teva Czech Industries S.R.O. Inhibidor de la cristalización y su uso en cápsulas de gelatina
CN101032620B (zh) * 2007-03-08 2010-05-19 上海凯昭医药科技有限公司 一种环孢素自乳化制剂及其制备方法
US20090130198A1 (en) * 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
EP2268274B1 (en) 2008-03-20 2012-05-16 Virun, Inc. Vitamin e derivatives and their uses
MX2010010050A (es) 2008-03-20 2011-03-15 Virun Inc Star Emulsiones que incluyen un derivado de polietilen glicol de tocoferol.
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
JP5567909B2 (ja) * 2010-06-17 2014-08-06 東洋カプセル株式会社 タクロリムス含有カプセル剤
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
JP5717034B2 (ja) * 2012-08-27 2015-05-13 丸和バイオケミカル株式会社 マクロライド系化合物を含有する土壌線虫防除用薬剤
KR101458466B1 (ko) * 2013-06-24 2014-11-07 한국화학연구원 면역억제제가 봉입된 마이셀을 함유하는 경구제
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
EP3349717A4 (en) 2015-09-17 2019-04-17 JRX Biotechnology, Inc. APPROACHES TO IMPROVE HYDRATION OR HUMIDIFICATION OF THE SKIN
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
PT3886813T (pt) * 2018-11-26 2023-04-26 Hepion Pharmaceuticals Inc Formulações farmacêuticas de análogos de ciclosporina
WO2024014958A2 (en) * 2022-07-15 2024-01-18 Seranovo Holding B.V. Lides formulation platform
WO2024014959A2 (en) * 2022-07-15 2024-01-18 Seranovo Holding B.V. Micelle-generating formulations with improved hydrophobicity
CN117797093A (zh) * 2024-02-29 2024-04-02 中国农业科学院农业环境与可持续发展研究所 一种以大环内酯类药物为活性成分的兽用口服纳米液体制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
JP2632010B2 (ja) * 1988-01-29 1997-07-16 三共株式会社 シクロスポリン製剤
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
EP0589843B1 (en) * 1992-09-25 2001-11-28 Novartis AG Pharmaceutical compositions containing cyclosporins
GB2278780B (en) * 1993-05-27 1998-10-14 Sandoz Ltd Macrolide formulations
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
EP0694308A4 (en) * 1994-02-17 1997-09-10 Shiseido Co Ltd CYCLOSPORIN EMULSION COMPOSITION
JP3131112B2 (ja) * 1994-02-17 2001-01-31 株式会社資生堂 シクロスポリン含有乳化組成物
IL129547A (en) * 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
EP0786986B1 (en) * 1994-10-26 2002-03-20 Novartis AG Use of an unsaturated fatty alcohol
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
KR970064620A (ko) * 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
KR980008239A (ko) * 1996-07-26 1998-04-30 김충환 사이클로스포린-함유 약학적 조성물
US6063762A (en) * 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
JP4761093B2 (ja) * 1997-12-10 2011-08-31 シクロスポリン セラポイティクス リミテッド オメガ−3脂肪酸油を含む医薬組成物

Also Published As

Publication number Publication date
BR9908597A (pt) 2000-11-14
FR2800277B1 (fr) 2004-06-25
FR2800277A1 (fr) 2001-05-04
HUP0101080A3 (en) 2001-12-28
PE20000324A1 (es) 2000-04-13
ES2228014T3 (es) 2005-04-01
CZ301967B6 (cs) 2010-08-18
KR20010041657A (ko) 2001-05-25
BE1012400A5 (fr) 2000-10-03
EP1354582A3 (en) 2004-06-09
NO20004299D0 (no) 2000-08-29
DE69920668T2 (de) 2005-10-06
AU749217B2 (en) 2002-06-20
TW200422057A (en) 2004-11-01
JP2004189753A (ja) 2004-07-08
ITMI990452A1 (it) 2000-09-05
JP2002505271A (ja) 2002-02-19
IL138248A (en) 2006-06-11
SK13192000A3 (sk) 2001-02-12
NO20004299L (no) 2000-08-29
GB0021495D0 (en) 2000-10-18
CA2322845A1 (en) 1999-09-10
EP1059913A1 (en) 2000-12-20
AU2836199A (en) 1999-09-20
FR2775596B1 (fr) 2004-12-24
CZ20003222A3 (cs) 2000-12-13
BE1013423A5 (fr) 2002-01-15
FR2853546B1 (fr) 2006-04-07
ATE277599T1 (de) 2004-10-15
IT1313550B1 (it) 2002-09-09
WO1999044584A1 (en) 1999-09-10
DE19983012T1 (de) 2001-02-01
TR200002586T2 (tr) 2000-11-21
KR100443306B1 (ko) 2004-08-09
EP1354582A2 (en) 2003-10-22
NO331800B1 (no) 2012-04-02
BE1013648A5 (fr) 2002-05-07
NZ506644A (en) 2004-02-27
HUP0101080A2 (hu) 2001-08-28
SK285139B6 (sk) 2006-07-07
HK1033277A1 (en) 2001-08-24
TWI257870B (en) 2006-07-11
TWI248368B (en) 2006-02-01
CN1292684A (zh) 2001-04-25
GB2350791A (en) 2000-12-13
TWI236912B (en) 2005-08-01
IL138248A0 (en) 2001-10-31
FR2775596A1 (fr) 1999-09-10
EP1059913B1 (en) 2004-09-29
CA2322845C (en) 2009-12-08
FR2853546A1 (fr) 2004-10-15
CN1195495C (zh) 2005-04-06
FR2881956A1 (fr) 2006-08-18
MY129274A (en) 2007-03-30
HK1034038A1 (en) 2001-10-12
ID25908A (id) 2000-11-09
PT1059913E (pt) 2005-01-31
DE69920668D1 (de) 2004-11-04
AR015729A1 (es) 2001-05-16
GB2350791B (en) 2003-04-02

Similar Documents

Publication Publication Date Title
CO4930289A1 (es) Composiciones galenicas, en donde el ingrediente activo es un agente activo dificilmente soluble
NO20000467L (no) Farmasøytisk preparat i form av en selvemulgerende formulering for lipofile forbindelser
KR900001364A (ko) 정맥주사용 약학적 조성물 및 이를 제조하는 방법
US8969307B2 (en) Cyclosporin compositions
EP1210063A1 (en) Compositions and methods for enhanced absorption of hydrophilic therapeutic agents
DK0957942T4 (da) Polymer-lipid-mikroindkapslede gasser til anvendelse som billeddannende midler
TR200102861T2 (tr) Uzun zincirli trigliseridler ve lipofilik surfaktantları içeren oral farmasötik kompozisyonlar.
EP0327280A1 (en) Cyclosporin compositions
EE9500063A (et) Farmatseutilised liposoomsüstepreparaadid
AR043106A2 (es) Formulaciones farmaceuticas para la administracion oral y topica y formas de dosis farmaceutica
ATE355053T1 (de) Pharmazeutische formulierung mit cyclosporin, propylenglycol-ester und nichtionischem tensid
KR20010003063A (ko) 미녹시딜 함유 외용 에멀젼 조성물
KR970706803A (ko) 경구용 시클로스포린 제형(oral cyclosporin formulations)
SK37198A3 (en) Cyclosporin-containing soft capsule preparations
KR100517653B1 (ko) 제제학적으로 안정한 연질캡슐의 조성물
RU2000125560A (ru) Предварительно приготовленные эмульсионные концентраты, содержащие циклоспорин или макролид